Open Government Portal
The purpose of this Notice of Amendment is to notify about the addition of sotrovimab to the Prescription Drug List (PDL) for human and veterinary use.
The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will revise the listing for Adrenocortical hormones on the Prescription Drug List (PDL) to exempt Triamcinolone acetonide.
The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing of Vitamin D on the Prescription Drug List (PDL) to allow non-prescription status for products a) containing up to 62.5 µg or 2,500 International Units (IU)/dosage form for oral use; or b) with a maximum recommended daily oral intake of 2,500 IU. Only the Human part of the PDL was revised.
The purpose of this Notice of Amendment is to notify about the additions of:
- Strain Russian BCG-I to the "including" column of the |Bacillus Calmette-Guérin (BCG)" entry on the Prescription Drug List for human and veterinary use,
- Bedinvetmab to the PDL for veterinary use, and
- Binimetinib, Brillant Blue G, encorafenib, eptinezumab, mecasermin, onasemnogene abeparvovec, ponesimod, ranolazine, triheptanoin and zanubrutinib to the PDL for human and veterinary use.
The purpose of this Notice of Amendment is to notify about the additions of the following medicinal ingredients on the Prescription Drug List (PDL) for human and veterinary use: Brexucabtagene autoleucel; Idecabtagene vicleucel; Pitolisant; Risdiplam; Selpercatinib; Solriamfetol; Tepotinib; Tildrakizumab; Trastuzumab; deruxtecan.
The purpose of this Notice of Amendment is to notify about the additions of: Elexacaftor, Inclisiran, Ospemifene, Pralsetinib and Tafasitamab to the Prescription Drug List (PDL) for human and veterinary use, and Frunevetmab to the PDL for veterinary use.
The purpose of this Notice of Amendment is to notify of the addition of the following medicinal ingredients on the Prescription Drug List (PDL) for human and veterinary use: Infigratinib or its salts, Lurbinectedin or its salts or derivatives, Pemigatinib or its salts, Propylthiouracil or its salts, Sacituzumab govitecan, and Sotorasib.
The purpose of this Notice of Amendment is to notify about the additions of Dequalinium chloride, Enfortumab vedotin, Somatrogon, and Tralokinumab to the Prescription Drug List (PDL) for human and veterinary use.
The purpose of this Notice of Amendment is to notify about the additions of gemtuzumab ozogamacin, gilteritinib, icosapent ethyl, tafamidis, trifarotine and upadacitinib to the Prescription Drug List (PDL) for human and/or veterinary use.
The purpose of this Notice of Amendment is to notify about the additions of Alpelisib, Baloxavir marboxil, Betula verrucosa (white birch), Brolucizumab, Cabotegravir, Caplacizumab, Ciclesonide, Darolutamide, Entrectinib, Fremanezumab, Glasdegib, Isatuximab, Siponimod, Tenapanor, Tetracosactide and Tucatinib to the Prescription Drug List (PDL) for human and/or veterinary use.